Uric Acid as a Mediator of Diabetic Nephropathy

Seminars in Nephrology

Volumn 31, Issue 5, 2011, Pages 459-465

  Jalal, Diana I ^a   Maahs, David M ^b   Hovind, Peter ^c,d   Nakagawa, Takahiko ^a  

^a UNIVERSITY OF COLORADO   (United States)

^b UNIVERSITY OF COLORADO DENVER   (United States)

^c GLOSTRUP UNIVERSITY HOSPITAL   (Denmark)

^d STENO DIABETES CENTER   (Denmark)

Author keywords

Diabetes; Kidney disease; Uric acid

Indexed keywords

ALLOPURINOL; ANGIOTENSIN RECEPTOR ANTAGONIST; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; LOSARTAN; PLACEBO; PROBENECID; URIC ACID;

ARTICLE; DIABETIC NEPHROPATHY; DIABETIC PATIENT; DISEASE COURSE; ENDOTHELIAL DYSFUNCTION; HUMAN; HYPERURICEMIA; INFLAMMATION; KIDNEY FAILURE; LOW DRUG DOSE; NONHUMAN; PATHOGENESIS; PATIENT CARE; PRIORITY JOURNAL; UNITED STATES;

ANIMALS; DIABETIC NEPHROPATHIES; DISEASE MODELS, ANIMAL; DISEASE PROGRESSION; HUMANS; URIC ACID;

EID: 80054055235     PISSN: 02709295     EISSN: 15584488     Source Type: Journal    
DOI: 10.1016/j.semnephrol.2011.08.011     Document Type: Article

References (93)

1. USRDS 2005 Annual Data Report. Atlas of End-Stage Renal Disease 2005, National Institutes of Health, Bethesda, MD.
2. KDOQI Clinical Practice Guidelines and Clinical Practice Recommendations for Diabetes and Chronic Kidney Disease. Am J Kidney Dis 2007, 49(Suppl 2):S12-S154.
3. Stenvinkel P. Chronic kidney disease: a public health priority and harbinger of premature cardiovascular disease. J Intern Med 2010, 268:456-467.
4. Keen H. The Diabetes Control and Complications Trial (DCCT). Health Trends 1994, 26:41-43.
5. Schrier R.W., Estacio R.O., Mehler P.S., Hiatt W.R. Appropriate blood pressure control in hypertensive and normotensive type 2 diabetes mellitus: a summary of the ABCD trial. Nat Clin Pract Nephrol 2007, 3:428-438.
6. Lewis E.J., Hunsicker L.G., Bain R.P., Rohde R.D. The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. The Collaborative Study Group. N Engl J Med 1993, 329:1456-1462.
7. Lewis E.J., Hunsicker L.G., Clarke W.R., Berl T., Pohl M.A., Lewis J.B., et al. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med 2001, 345:851-860.
8. Brenner B.M., Cooper M.E., de Zeeuw D., Keane W.F., Mitch W.E., Parving H.H., et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 2001, 345:861-869.
9. Border W.A., Noble N.A. Evidence that TGF-beta should be a therapeutic target in diabetic nephropathy. Kidney Int 1998, 54:1390-1391.
10. Chen S., Hong S.W., Iglesias-de la Cruz M.C., Isono M., Casaretto A., Ziyadeh F.N. The key role of the transforming growth factor-beta system in the pathogenesis of diabetic nephropathy. Renal Fail 2001, 23:471-481.
11. Ziyadeh F.N., Hoffman B.B., Han D.C., Iglesias-De La Cruz M.C., Hong S.W., Isono M., et al. Long-term prevention of renal insufficiency, excess matrix gene expression, and glomerular mesangial matrix expansion by treatment with monoclonal antitransforming growth factor-beta antibody in db/db diabetic mice. Proc Natl Acad Sci U S A 2000, 97:8015-8020.
12. Yamamoto T., Nakamura T., Noble N.A., Ruoslahti E., Border W.A. Expression of transforming growth factor beta is elevated in human and experimental diabetic nephropathy. Proc Natl Acad Sci U S A 1993, 90:1814-1818.
13. Nakamura T., Fukui M., Ebihara I., Osada S., Nagaoka I., Tomino Y., et al. mRNA expression of growth factors in glomeruli from diabetic rats. Diabetes 1993, 42:450-456.
14. Sharma K., Jin Y., Guo J., Ziyadeh F.N. Neutralization of TGF-beta by anti-TGF-beta antibody attenuates kidney hypertrophy and the enhanced extracellular matrix gene expression in STZ-induced diabetic mice. Diabetes 1996, 45:522-530.
15. Sharma K., Ziyadeh F.N. Renal hypertrophy is associated with upregulation of TGF-beta 1 gene expression in diabetic BB rat and NOD mouse. Am J Physiol 1994, 267:F1094-F1101.
16. Riser B.L., Cortes P., Yee J., Sharba A.K., Asano K., Rodriguez-Barbero A., et al. Mechanical strain- and high glucose-induced alterations in mesangial cell collagen metabolism: role of TGF-beta. J Am Soc Nephrol 1998, 9:827-836.
17. Riser B.L., Ladson-Wofford S., Sharba A., Cortes P., Drake K., Guerin C.J., et al. TGF-beta receptor expression and binding in rat mesangial cells: modulation by glucose and cyclic mechanical strain. Kidney Int 1999, 56:428-439.
18. Ziyadeh F.N., Sharma K., Ericksen M., Wolf G. Stimulation of collagen gene expression and protein synthesis in murine mesangial cells by high glucose is mediated by autocrine activation of transforming growth factor-beta. J Clin Invest 1994, 93:536-542.
19. Ayo S.H., Radnik R.A., Garoni J.A., Glass W.F., Kreisberg J.I. High glucose causes an increase in extracellular matrix proteins in cultured mesangial cells. Am J Pathol 1990, 136:1339-1348.
20. Haneda M., Kikkawa R., Horide N., Togawa M., Koya D., Kajiwara N., et al. Glucose enhances type IV collagen production in cultured rat glomerular mesangial cells. Diabetologia 1991, 34:198-200.
21. Hayashi K., Epstein M., Loutzenhiser R., Forster H. Impaired myogenic responsiveness of the afferent arteriole in streptozotocin-induced diabetic rats: role of eicosanoid derangements. J Am Soc Nephrol 1992, 2:1578-1586.
22. Bidani A.K., Griffin K.A., Picken M., Lansky D.M. Continuous telemetric blood pressure monitoring and glomerular injury in the rat remnant kidney model. Am J Physiol 1993, 265:F391-F398.
23. Riser B.L., Cortes P., Zhao X., Bernstein J., Dumler F., Narins R.G. Intraglomerular pressure and mesangial stretching stimulate extracellular matrix formation in the rat. J Clin Invest 1992, 90:1932-1943.
24. Riser B.L., Cortes P., Heilig C., Grondin J., Ladson-Wofford S., Patterson D., et al. Cyclic stretching force selectively up-regulates transforming growth factor-beta isoforms in cultured rat mesangial cells. Am J Pathol 1996, 148:1915-1923.
25. Koya D., King G.L. Protein kinase C activation and the development of diabetic complications. Diabetes 1998, 47:859-866.
26. Haneda M., Araki S., Togawa M., Sugimoto T., Isono M., Kikkawa R. Mitogen-activated protein kinase cascade is activated in glomeruli of diabetic rats and glomerular mesangial cells cultured under high glucose conditions. Diabetes 1997, 46:847-853.
27. Haneda M., Kikkawa R., Arimura T., Ebata K., Togawa M., Maeda S., et al. Glucose inhibits myo-inositol uptake and reduces myo-inositol content in cultured rat glomerular mesangial cells. Metabolism 1990, 39:40-45.
28. Suzuki D., Miyata T., Saotome N., Horie K., Inagi R., Yasuda Y., et al. Immunohistochemical evidence for an increased oxidative stress and carbonyl modification of proteins in diabetic glomerular lesions. J Am Soc Nephrol 1999, 10:822-832.
29. Brownlee M., Cerami A., Vlassara H. Advanced glycosylation end products in tissue and the biochemical basis of diabetic complications. N Engl J Med 1988, 318:1315-1321.
30. Koya D., Haneda M., Nakagawa H., Isshiki K., Sato H., Maeda S., et al. Amelioration of accelerated diabetic mesangial expansion by treatment with a PKC beta inhibitor in diabetic db/db mice, a rodent model for type 2 diabetes. FASEB J 2000, 14:439-447.
31. Derubertis F.R., Craven P.A. Activation of protein kinase C in glomerular cells in diabetes. Mechanisms and potential links to the pathogenesis of diabetic glomerulopathy. Diabetes 1994, 43:1-8.
32. Barnard J.A., Lyons R.M., Moses H.L. The cell biology of transforming growth factor beta. Biochim Biophys Acta 1990, 1032:79-87.
33. Massague J. The transforming growth factor-beta family. Ann Rev Cell Biol 1990, 6:597-641.
34. Prud'homme G.J., Piccirillo C.A. The inhibitory effects of transforming growth factor-beta-1 (TGF-beta1) in autoimmune diseases. J Autoimmun 2000, 14:23-42.
35. McCartney-Francis N.L., Frazier-Jessen M., Wahl S.M. TGF-beta: a balancing act. Int Rev Immunol 1998, 16:553-580.
36. Shull M.M., Ormsby I., Kier A.B., Pawlowski S., Diebold R.J., Yin M., et al. Targeted disruption of the mouse transforming growth factor-beta 1 gene results in multifocal inflammatory disease. Nature 1992, 359:693-699.
37. Edwards N.L. The role of hyperuricemia and gout in kidney and cardiovascular disease. Cleve Clin J Med 2008, 75(Suppl 5):S13-S16.
38. Dalbeth N., Stamp L. Allopurinol dosing in renal impairment: walking the tightrope between adequate urate lowering and adverse events. Semin Dial 2007, 20:391-395.
39. Kodama S., Saito K., Yachi Y., Asumi M., Sugawara A., Totsuka K., et al. Association between serum uric acid and development of type 2 diabetes. Diabetes Care 2009, 32:1737-1742.
40. Johnson R.J., Perez-Pozo S.E., Sautin Y.Y., Manitius J., Sanchez-Lozada L.G., Feig D.I., et al. Hypothesis: could excessive fructose intake and uric acid cause type 2 diabetes?. Endocr Rev 2009, 30:96-116.
41. Waring W.S., McKnight J.A., Webb D.J., Maxwell S.R. Uric acid restores endothelial function in patients with type 1 diabetes and regular smokers. Diabetes 2006, 55:3127-3132.
42. Scott G.S., Cuzzocrea S., Genovese T., Koprowski H., Hooper D.C. Uric acid protects against secondary damage after spinal cord injury. Proc Natl Acad Sci U S A 2005, 102:3483-3488.
43. Waring W.S., Adwani S.H., Breukels O., Webb D.J., Maxwell S.R. Hyperuricaemia does not impair cardiovascular function in healthy adults. Heart 2004, 90:155-159.
44. Zharikov S., Krotova K., Hu H., Baylis C., Johnson R.J., Block E.R., et al. Uric acid decreases NO production and increases arginase activity in cultured pulmonary artery endothelial cells. Am J Physiol Cell Physiol 2008, 295:C1183-C1190.
45. Khosla U.M., Zharikov S., Finch J.L., Nakagawa T., Roncal C., Mu W., et al. Hyperuricemia induces endothelial dysfunction. Kidney Int 2005, 67:1739-1742.
46. Kang D.H., Park S.K., Lee I.K., Johnson R.J. Uric acid-induced C-reactive protein expression: implication on cell proliferation and nitric oxide production of human vascular cells. J Am Soc Nephrol 2005, 16:3553-3562.
47. Gersch C., Palii S.P., Kim K.M., Angerhofer A., Johnson R.J., Henderson G.N. Inactivation of nitric oxide by uric acid. Nucleosides Nucleotides Nucleic Acids 2008, 27:967-978.
48. Mazzali M., Hughes J., Kim Y.G., Jefferson J.A., Kang D.H., Gordon K.L., et al. Elevated uric acid increases blood pressure in the rat by a novel crystal-independent mechanism. Hypertension 2001, 38:1101-1106.
49. Sanchez-Lozada L.G., Tapia E., Lopez-Molina R., Nepomuceno T., Soto V., Avila-Casado C., et al. Effects of acute and chronic L-arginine treatment in experimental hyperuricemia. Am J Physiol 2007, 292:F1238-F1244.
50. George J., Carr E., Davies J., Belch J.J., Struthers A. High-dose allopurinol improves endothelial function by profoundly reducing vascular oxidative stress and not by lowering uric acid. Circulation 2006, 114:2508-2516.
51. Mazzali M., Kanellis J., Han L., Feng L., Xia Y.Y., Chen Q., et al. Hyperuricemia induces a primary renal arteriolopathy in rats by a blood pressure-independent mechanism. Am J Physiol Renal Physiol 2002, 282:F991-F997.
52. Roncal C.A., Mu W., Croker B., Reungjui S., Ouyang X., Tabah-Fisch I., et al. Effect of elevated serum uric acid on cisplatin-induced acute renal failure. Am J Physiol 2007, 292:F116-F122.
53. Kang D.H., Nakagawa T., Feng L., Watanabe S., Han L., Mazzali M., et al. A role for uric acid in the progression of renal disease. J Am Soc Nephrol 2002, 13:2888-2897.
54. Netea M.G., Kullberg B.J., Blok W.L., Netea R.T., van der Meer J.W. The role of hyperuricemia in the increased cytokine production after lipopolysaccharide challenge in neutropenic mice. Blood 1997, 89:577-582.
55. Talaat K.M., el-Sheikh A.R. The effect of mild hyperuricemia on urinary transforming growth factor beta and the progression of chronic kidney disease. Am J Nephrol 2007, 27:435-440.
56. Massague J. How cells read TGF-beta signals. Nat Rev Mol Cell Biol 2000, 1:169-178.
57. Choi M.E. Mechanism of transforming growth factor-beta1 signaling. Kidney Int Suppl 2000, 77:S53-S58.
58. Kanellis J., Watanabe S., Li J.H., Kang D.H., Li P., Nakagawa T., et al. Uric acid stimulates monocyte chemoattractant protein-1 production in vascular smooth muscle cells via mitogen-activated protein kinase and cyclooxygenase-2. Hypertension 2003, 41:1287-1293.
59. Nakagawa T., Sato W., Glushakova O., Heinig M., Clarke T., Campbell-Thompson M., et al. Diabetic endothelial nitric oxide synthase knockout mice develop advanced diabetic nephropathy. J Am Soc Nephrol 2007, 18:539-550.
60. Kosugi T., Nakayama T., Heinig M., Zhang L., Yuzawa Y., Sanchez-Lozada L.G., et al. The effect of lowering uric acid on renal disease in the type 2 diabetic db/db mice. Am J Physiol Renal Physiol 2009, 297:F481-F488.
61. Han H.J., Lim M.J., Lee Y.J., Lee J.H., Yang I.S., Taub M. Uric acid inhibits renal proximal tubule cell proliferation via at least two signaling pathways involving PKC, MAPK, cPLA2, and NF-kappaB. Am J Physiol Renal Physiol 2007, 292:F373-F381.
62. Johnson R.J., Kang D.H., Feig D., Kivlighn S., Kanellis J., Watanabe S., et al. Is there a pathogenetic role for uric acid in hypertension and cardiovascular and renal disease?. Hypertension 2003, 41:1183-1190.
63. Rosolowsky E.T., Ficociello L.H., Maselli N.J., Niewczas M.A., Binns A.L., Roshan B., et al. High-normal serum uric acid is associated with impaired glomerular filtration rate in nonproteinuric patients with type 1 diabetes. Clin J Am Soc Nephrol 2008, 3:706-713.
64. Hsu C.Y., Iribarren C., McCulloch C.E., Darbinian J., Go A.S. Risk factors for end-stage renal disease: 25-year follow-up. Arch Intern Med 2009, 169:342-350.
65. Obermayr R.P., Temml C., Gutjahr G., Knechtelsdorfer M., Oberbauer R., Klauser-Braun R. Elevated uric acid increases the risk for kidney disease. J Am Soc Nephrol 2008, 19:2407-2413.
66. Weiner D.E., Tighiouart H., Elsayed E.F., Griffith J.L., Salem D.N., Levey A.S. Uric acid and incident kidney disease in the community. J Am Soc Nephrol 2008, 19:1204-1211.
67. Borges R.L., Hirota A.H., Quinto B.M., Ribeiro A.B., Zanella M.T., Batista M.C. Uric acid as a marker for renal dysfunction in hypertensive women on diuretic and nondiuretic therapy. J Clin Hypertens (Greenwich) 2009, 11:253-259.
68. Park J.T., Kim D.K., Chang T.I., Kim H.W., Chang J.H., Park S.Y., et al. Uric acid is associated with the rate of residual renal function decline in peritoneal dialysis patients. Nephrol Dial Transplant 2009, 24:3520-3525.
69. Chonchol M., Shlipak M.G., Katz R., Sarnak M.J., Newman A.B., Siscovick D.S., et al. Relationship of uric acid with progression of kidney disease. Am J Kidney Dis 2007, 50:239-247.
70. Sturm G., Kollerits B., Neyer U., Ritz E., Kronenberg F. Uric acid as a risk factor for progression of non-diabetic chronic kidney disease?. The Mild to Moderate Kidney Disease (MMKD) study. Exp Gerontol 2008, 43:347-352.
71. Madero M., Sarnak M.J., Wang X., Greene T., Beck G.J., Kusek J.W., et al. Uric acid and long-term outcomes in CKD. Am J Kidney Dis 2009, 53:796-803.
72. Hovind P., Rossing P., Tarnow L., Johnson R.J., Parving H.H. Serum uric acid as a predictor for development of diabetic nephropathy in type 1 diabetes-an inception cohort study. Diabetes 2009, 58:1668-1671.
73. Jalal D.I., Rivard C.J., Johnson R.J., Maahs D.M., McFann K., Rewers M., et al. Serum uric acid levels predict the development of albuminuria over 6 years in patients with type 1 diabetes: findings from the Coronary Artery Calcification in Type 1 Diabetes study. Nephrol Dial Transplant 2010, 25:1865-1869.
74. Ficociello L.H., Rosolowsky E.T., Niewczas M.A., Maselli N.J., Weinberg J.M., Aschengrau A., et al. High-normal serum uric acid increases risk of early progressive renal function loss in type 1 diabetes: results of a 6-year follow-up. Diabetes Care 2010, 33:1337-1343.
75. Siu Y.P., Leung K.T., Tong M.K., Kwan T.H. Use of allopurinol in slowing the progression of renal disease through its ability to lower serum uric acid level. Am J Kidney Dis 2006, 47:51-59.
76. Goicoechea M., de Vinuesa S.G., Verdalles U., Ruiz-Caro C., Ampuero J., Rincon A., et al. Effect of allopurinol in chronic kidney disease progression and cardiovascular risk. Clin J Am Soc Nephrol 2010, 5:1388-1393.
77. Momeni A., Shahidi S., Seirafian S., Taheri S., Kheiri S. Effect of allopurinol in decreasing proteinuria in type 2 diabetic patients. Iran J Kidney Dis 2010, 4:128-132.
78. Miao Y., Ottenbros S.A., Laverman G.D., Brenner B.M., Cooper M.E., Parving H.H., et al. Effect of a reduction in uric acid on renal outcomes during losartan treatment: a post hoc analysis of the reduction of endpoints in non-insulin-dependent diabetes mellitus with the angiotensin ii antagonist losartan trial. Hypertension 2011, 58:2-7.
79. Keith D.S., Nichols G.A., Gullion C.M., Brown J.B., Smith D.H. Longitudinal follow-up and outcomes among a population with chronic kidney disease in a large managed care organization. Arch Intern Med 2004, 164:659-663.
80. Brantsma A.H., Bakker S.J., Hillege H.L., de Zeeuw D., de Jong P.E., Gansevoort R.T. Cardiovascular and renal outcome in subjects with K/DOQI stage 1-3 chronic kidney disease: the importance of urinary albumin excretion. Nephrol Dial Transplant 2008, 23:3851-3858.
81. Go A.S., Chertow G.M., Fan D., McCulloch C.E., Hsu C.Y. Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N Engl J Med 2004, 351:1296-1305.
82. McCullough P.A., Jurkovitz C.T., Pergola P.E., McGill J.B., Brown W.W., Collins A.J., et al. Independent components of chronic kidney disease as a cardiovascular risk state: results from the Kidney Early Evaluation Program (KEEP). Arch Intern Med 2007, 167:1122-1129.
83. McCullough P.A., Li S., Jurkovitz C.T., Stevens L., Collins A.J., Chen S.C., et al. Chronic kidney disease, prevalence of premature cardiovascular disease, and relationship to short-term mortality. Am Heart J 2008, 156:277-283.
84. Weiner D.E., Tighiouart H., Stark P.C., Amin M.G., MacLeod B., Griffith J.L., et al. Kidney disease as a risk factor for recurrent cardiovascular disease and mortality. Am J Kidney Dis 2004, 44:198-206.
85. Whaley-Connell A.T., Sowers J.R., Stevens L.A., McFarlane S.I., Shlipak M.G., Norris K.C., et al. CKD in the United States: Kidney Early Evaluation Program (KEEP) and National Health and Nutrition Examination Survey (NHANES) 1999-2004. Am J Kidney Dis 2008, 51(Suppl 2):S13-S20.
86. Rao M.V., Qiu Y., Wang C., Bakris G. Hypertension and CKD: Kidney Early Evaluation Program (KEEP) and National Health and Nutrition Examination Survey (NHANES), 1999-2004. Am J Kidney Dis 2008, 51(Suppl 2):S30-S37.
87. Sarnak M.J., Coronado B.E., Greene T., Wang S.R., Kusek J.W., Beck G.J., et al. Cardiovascular disease risk factors in chronic renal insufficiency. Clin Nephrol 2002, 57:327-335.
88. Suliman M.E., Johnson R.J., Garcia-Lopez E., Qureshi A.R., Molinaei H., Carrero J.J., et al. J-shaped mortality relationship for uric acid in CKD. Am J Kidney Dis 2006, 48:761-771.
89. Hsu S.P., Pai M.F., Peng Y.S., Chiang C.K., Ho T.I., Hung K.Y. Serum uric acid levels show a 'J-shaped' association with all-cause mortality in haemodialysis patients. Nephrol Dial Transplant 2004, 19:457-462.
90. Weiner D.E., Tighiouart H., Elsayed E.F., Griffith J.L., Salem D.N., Levey A.S., et al. The relationship between nontraditional risk factors and outcomes in individuals with stage 3 to 4 CKD. Am J Kidney Dis 2008, 51:212-223.
91. Navaneethan S.D., Beddhu S. Associations of serum uric acid with cardiovascular events and mortality in moderate chronic kidney disease. Nephrol Dial Transplant 2009, 24:1260-1266.
92. Rathmann W., Hauner H., Dannehl K., Gries F.A. Association of elevated serum uric acid with coronary heart disease in diabetes mellitus. Diabete Metab 1993, 19:159-166.
93. Kao M.P., Ang D.S., Gandy S.J., Nadir M.A., Houston J.G., Lang C.C., et al. Allopurinol benefits left ventricular mass and endothelial dysfunction in chronic kidney disease. J Am Soc Nephrol 2011, 22:1382-1389.